Research and Clinical Trials on Venlafaxine (Effexor, Efexor)

avatar image
By Dr Greg Mulhauser

This list of current clinical research trials on Venlafaxine (Effexor, Efexor) is followed by a short set of abstracts from the most recent research articles published on the drug.

Article Contents

Venlafaxine (Effexor, Efexor) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Venlafaxine (Effexor, Efexor).

 

Get These Clinical Trials as a Newsfeed

Venlafaxine:     Get the Venlafaxine clinical trials feed.    Add the Venlafaxine clinical trials feed to your My Yahoo! page.    Add the Venlafaxine clinical trials feed to your MyMSN page.

Current Research Literature on Venlafaxine (Effexor, Efexor)

Here are abstracts for some of the latest research articles to have appeared on Venlafaxine (Effexor, Efexor):

Advanced formulation design of venlafaxine hydrochloride coated and triple-layer tablets containing hypromellose.

Pharm Dev Technol. 2009 Dec; 14(6): 650-658
Gohel M, Bariya SH
The purpose of this research work was to develop venlafaxine hydrochloride-coated and layered matrix tablets using hypromellose adopting wet granulation technique. The granules and the tablets were characterized. The monolithic tablets were coated with different ratios of ethyl cellulose and hypromellose. The in vitro dissolution study was performed in distilled water. In the layered tablets, the middle layer containing drug was covered with barrier layers containing high viscosity grade hypromellose. Simplex lattice design was used for formulating the layered tablets. The dissolution study of the optimized batches and a reference product was carried out in 0.1 N HCl, phosphate buffer and hydroalcoholic solution. Burst drug release was exhibited by the uncoated tablets, probably due to high aqueous solubility of venlafaxine HCl. The coated tablets showed sustained drug release without burst effect. The drug release was best explained by Weibull model. A unified Weibull equation was evolved to express drug release from the coated tablets. The layered tablets also exhibited sustained release without burst effect due to effective area reduction. The optimized batches showed identical drug release in 0.1 N HCl, phosphate buffer and 10% v/v aqueous alcohol. Layered tablets may well be adopted by the industry due to the possibility of achieving a high production rate.

Long-term response to successful acute pharmacological treatment of psychotic depression.

J Affect Disord. 2009 Oct 30;
Wijkstra J, Burger H, van den Broek WW, Birkenhäger TK, Janzing JG, Boks MP, Bruijn JA, van der Loos ML, Breteler LM, Verkes RJ, Nolen WA
BACKGROUND: Data about follow-up after acute pharmacological treatment of psychotic depression are scarce. METHODS: A 4month open follow-up was done, preferentially with same medication as during acute treatment, of patients (n=59) with DSM-IV-TR major depressive disorder with psychotic features, aged 18 to 65years, who had completed as responders an acute double-blind 7week trial with imipramine, venlafaxine or venlafaxine plus quetiapine. Main outcome measures were Hamilton Rating Scale for Depression and Clinical Global Impression Scale. RESULTS: Six patients dropped out during the 4month follow-up. Almost all patients (86.4%; 51/59) remained responder while remission rate increased from 59.3% (35/59) to 86.8% (46/53), independent of treatment. Relapse rate was low (3.8%; 2/53). Tolerability was good. Weight increased with all treatments. LIMITATIONS: Limitations were the limited sample size and consequent limited statistical power. The treatment during follow-up was not double-blind. CONCLUSIONS: Continuation treatment with the same medication that was effective in the acute treatment trial, remained effective during the 4month follow-up in many patients leading to further improvement, and was well tolerated.

Evidence-based interventional pain medicine according to clinical diagnoses. 3. Persistent idiopathic facial pain.

Pain Pract. 2009 Nov-Dec; 9(6): 443-8
Cornelissen P, van Kleef M, Mekhail N, Day M, van Zundert J
Persistent idiopathic facial pain, previously known as atypical facial pain, is described as a persistent facial pain that does not have the classical characteristics of cranial neuralgias and for which there is no obvious cause (International Classification of Headache Disorders in 2004). According to these criteria, the diagnosis is possible if the facial pain is localized, present daily, and throughout all or most of the day. By definition, neurological and physical examination findings in persistent idiopathic facial pain should be normal. Forming a diagnosis is not simple and follows a process of elimination of other causes of facial pain. The precise incidence is unknown. The affliction is seen primarily in older adults and rarely in children. The pathophysiology is unknown. In persistent idiopathic facial pain, there is no abnormal processing of somatosensory stimuli in the pain area or facial area of the primary somatosensory cortex of the brain. The treatment is difficult and often requires a multidisciplinary approach. The most important part of the treatment is psychological counseling and pharmacological therapy. Pharmacological treatment with tricyclic antidepressants and anti-epileptic drugs can be tried. The conservative, pharmacological treatment with amitryptiline is the primary choice. Venlafaxine and fluoxetine treatment can also be considered. When the pharmacological treatment fails, pulsed radiofrequency treatment of the ganglion pterygopalatinum (sphenopalatinum) can be considered (2 C+).

A comparative study of non-fatal self-poisoning with antidepressants relative to prescribing in three centres in England.

J Affect Disord. 2009 Oct 26;
Bergen H, Murphy E, Cooper J, Kapur N, Stalker C, Waters K, Hawton K
BACKGROUND: Antidepressants are used frequently in non-fatal self-poisoning. There are national guidelines for prescribing antidepressants. There have been few investigations of how non-fatal self-poisoning with antidepressants varies in relation to prescribing and to patient characteristics. METHODS: A comparative study of the use of specific antidepressants (amitriptyline and dosulepin (tricyclics), citalopram, fluoxetine, paroxetine and sertraline (selective serotonin reuptake inhibitors) and venlafaxine (serotonin norepinephrine reuptake inhibitor)) for non-fatal self-poisoning (episode-based), relative to prescribing, in three centres in England, 2004 to 2006. RESULTS: There was marked variation between centres in the ratio of rates of self-poisoning to prescribing for specific antidepressants. Higher rates of self-poisoning relative to prescribing for all antidepressants combined, and for venlafaxine, were found in the centre with greater proportions of patients with a history of self-harm and/or previous psychiatric treatment. Within each centre, higher rates of self-poisoning relative to prescribing were found for citalopram and fluoxetine than amitriptyline. However, rates of self-poisoning relative to prescribing for either amitriptyline or dosulepin were also similar to sertraline, which is of concern given the known toxicity of tricyclics. LIMITATIONS: An ecological study, where prescriptions were for all indications and not specifically for the patients who self-poisoned. CONCLUSIONS: Marked differences found in ratios of self-poisoning with antidepressants to levels of prescribing, in three centres in England, are likely to reflect differences in both prescribing practices (despite clear national guidance) and patient characteristics. Risk of overdose and toxicity should be considered when local prescribing policy and clinical practice relating to antidepressants are under review.

Gestational Exposure to Antidepressants and the Risk of Spontaneous Abortion: A Review.

Curr Drug Deliv. 2009 Oct 29;
Broy P, BĂ©rard A
Background. Although the relationship between antidepressant use during pregnancy and its adverse effects has been widely investigated, very few studies have evaluated the impact of antidepressant use during pregnancy on the risk of spontaneous abortion. We present an overview of the evidence relating to the association between antidepressant use during gestation and the risk of spontaneous abortion. Methods. We systematically searched PubMed and the reference lists of all relevant articles, including reviews, published in English or French from 1975 through 2009 for studies that examined the association between adverse pregnancy outcomes and gestational exposure to antidepressants with data on spontaneous abortions. Only etiologic studies were considered. Results. Fifteen studies met inclusion criteria. The majority of these were prospective cohort studies on tricyclics antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs) use during pregnancy. Overall, in unadjusted analyses, fluoxetine (OR = 2.0; 95% CI = 1.4 - 3.0) and bupropion (OR = 4.1; 95% CI = 1.5 - 11.1) were significantly associated with the risk of spontaneous abortion. However, in adjusted analyses, only paroxetine (OR = 1.7; 95% CI = 1.3 - 2.3) and venlafaxine (OR = 2.1; 95% CI = 1.3 - 3.3) were significantly associated with the risk of spontaneous abortion. Conclusions. This review suggests that gestational exposure to antidepressants, especially paroxetine and venlafaxine, can lead to spontaneous abortion.

 

This page was last reviewed by Dr Greg Mulhauser, Monday, 1 June 2009.

The URL of this page is:
http://counsellingresource.com/medications/trials-and-research/venlafaxine-research.html